Spisulosine (ES-285) given as a weekly three-hour intravenous infusion: results of a phase I dose-escalating study in patients with advanced solid malignancies

P. Schoffski, H. Dumez, R. Ruijter, B. Miguel-Lillo, A. Soto-Matos, V. Alfaro, G. Giaccone

Research output: Contribution to journalArticleAcademicpeer-review

97 Downloads (Pure)
Original languageUndefined/Unknown
Pages (from-to)1397-1403
JournalCancer Chemotherapy and Pharmacology
Issue number6
Publication statusPublished - 2011

Cite this